Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: A critical and systematic review

PharmacoEconomics

Volumn 28, Issue 8, 2010, Pages 629-647

  Blank, Patricia R ^a   Dedes, Konstantin J ^b   Szucs, Thomas D ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Advanced breast cancer, treatment; Anthracyclines, therapeutic use; Antineoplastics, therapeutic use; Cost effectiveness; HER2 inhibitors, therapeutic use; Monoclonal antibodies, therapeutic use; Taxanes, therapeutic use; Trastuzumab, therapeutic use

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTHRACYCLINE PLUS CYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE DERIVATIVE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; IXABEPILONE; LAPATINIB; NANOPARTICLE ALBUMIN BOUND PACLITAXEL; PACLITAXEL; PACLITAXEL DERIVATIVE; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CYTOTOXICITY; EUROPE; HEALTH CARE COST; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 77954507007     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11535560-000000000-00000     Document Type: Review

References (75)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365 (9472): 1687-1717
2. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol 2002; 20: 620-623
3. Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 2009; 14: 645-656
4. Morris PG, McArthur HL, Hudis CA. Therapeutic options for metastatic breast cancer. Expert Opin Pharmacother 2009; 10: 967-981
5. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51
6. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
8. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274
9. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648
10. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712
11. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-184
12. Breuer B, Smith S, Thor A, et al. ErbB-2 protein in sera and tumors of breast cancer patients. Breast Cancer Res Treat 1998; 49: 261-270
13. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743
14. Morris PG, Hudis CA. Personalizing therapy for metastatic breast cancer. Expert Rev Anticancer Ther 2009; 9: 1223-1226
15. Albanell J, Montagut C, Jones ET, et al. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 2726-2731
16. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676
17. US National Institutes of Health; National Cancer Institute. FDA approval for bevacizumab [online]. Available from URL: http://www.cancer.gov/ cancertopics/druginfo/fdabevacizumab# Anchor-Metastati-43353 [Accessed 2010 Mar 23]
18. Kroese M, Zimmern RL, Pinder SE. HER2 status in breast cancer: an example of pharmacogenetic testing. J R Soc Med 2007; 100: 326-329
19. Szucs TD, Dedes KJ. Balancing costs and benefits in cancer therapy and prevention. Ann Oncol 2008; 19 Suppl. 7: vii313-9
20. Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 2007; 25: 191-195
21. Benedict A, Cameron DA, Corson H, et al. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK. Pharmacoeconomics 2009; 27: 847-859
22. Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 2009; 115: 489-498
23. Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45: 1397-1406
24. Vu T, Ellard S, Speers CH, et al. Survival outcome and costeffectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation. Ann Oncol 2008; 19: 461-464
25. Perez-Ellis C, Goncalves A, Jacquemier J, et al. Costeffectiveness analysis of trastuzumab (Herceptin) in HER2- overexpressed metastatic breast cancer. Am J Clin Oncol. Epub 2009 Jul 18
26. Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol 2008; 31: 363-368
27. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005; 16: 909-914
28. Reed SD, Li Y, Anstrom KJ, et al. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2009; 27: 2185-2191
29. Hornberger J, Kerrigan M, Foutel V. Cost-effectiveness of trastuzumab (Herceptin) for treatment of metastatic breast cancer [abstract]. Ann Oncol 2002; 13 Suppl. 5: 52
30. Garrison Jr LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health. Epub 2009 Jul 14
31. Dranitsaris G, Coleman R, Gradishar W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 2010; 119 (3): 717-724
32. Maniadakis N, Dafni U, Fragoulakis V, et al. Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial. Ann Oncol 2009; 20: 278-285
33. Reed SD, Li Y, Anstrom KJ, et al. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2009; 27: 2185-2191
34. Vu T, Ellard S, Speers CH, et al. Survival outcome and costeffectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation. Ann Oncol 2008; 19: 461-464
35. Benedict A, Cameron DA, Corson H, et al. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK. Pharmacoeconomics 2009; 27 (10): 847-859
36. Verma S, Ilersich AL. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline- pretreated metastatic breast cancer. Oncologist 2003; 8: 232-240
37. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005; 16: 909-914
38. Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol 2008; 31: 363-368
39. Garrison Jr LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health. Epub 2009 Jul 14
40. Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45: 1397-1406
41. Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 2009; 115: 489-498
42. Fountzilas G, Dafni U, Dimopoulos MA, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009; 115: 87-99
43. Fountzilas G, Dafni U, Dimopoulos MA, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009; 115: 87-99
44. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-5551
45. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-7803
46. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-5551
47. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 2007; 7: 919-943
48. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26: 1642-1649
49. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823
50. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 3611-3619
51. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25: 3399-3406
52. Lechleider RJ, Kaminskas E, Jiang X, et al. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res 2008; 14: 4378-4384
53. American Society for Clinical Oncology (ASCO); 2004 Jun 5-8; New Orleans (LA)
54. 26th Annual San Antonio Breast Cancer Symposium; 2003 Dec 3-6; San Antonio (TX)
55. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
56. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26: 5544-5552
57. US National Institutes of Health. National Cancer Institute. Phase III randomized study of capecitabine with versus without lapatinib in women with refractory locally advanced or metastatic breast cancer [online]. Available from URL: http://www.cancer.gov/clinicaltrials/GSK-EGF100151 [Accessed 2010 Mar 23]
58. Maniadakis N, Dafni U, Fragoulakis V, et al. Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial. Ann Oncol 2009; 20: 278-285
59. Garrison Jr LP, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007; 110 (3): 489-498
60. Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005 Dec; 6 (5): 425-432
61. Bonneterre ME, Bonneterre J. Reply to the article 'A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis', by J. Norum et al. (Ann Oncol 2005; 16: 909-914). Ann Oncol 2006; 17 (5): 875; reply 875-876
62. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004; 7: 43-49
63. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332: 699-703
64. Goeree R, Burke N, O'Reilly D, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007; 23: 671-682
65. Essers BA, Seferina SC, Tjan-Heijnen VC, et al. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. Value Health. Epub 2010 Jan 15
66. Dranitsaris G, Cottrell W, Spirovski B, et al. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract 2009; 15: 67-78
67. Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999; 282: 1453-1457
68. Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008; 112: 1455-1461
69. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26 (10): 1642-1649
70. Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1997; 336: 92-99
71. Trippoli S, Messori A. Cost-effectiveness analyses of statistically ineffective treatments. JAMA 1998; 280: 1992-1993
72. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-1258
73. Chan AL, Leung HW, Lu CL, et al. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother 2009; 43: 296-303
74. Garrison Jr LP, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007; 110: 489-498
75. Chapman RH, Berger M, Weinstein MC, et al. When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ 2004; 13: 429-436